Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06890338 · ClinicalTrials.gov registry record · Phase 2

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

A Phase 2 study of Fallopian Tube Cancer and Epithelial Ovarian Cancer, sponsored by AbbVie.

Recruiting
Registry status
Phase 2
Development phase
140
Enrollment target
20
Study locations

NCT06890338 is a Phase 2 study of Fallopian Tube Cancer and Epithelial Ovarian Cancer that is actively recruiting participants, run by AbbVie. The registered enrollment target is 140 participants, below the 254-participant average among 85 other Fallopian Tube Cancer trials with a reported enrollment target (45% lower). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06890338, a Phase 2 study of Fallopian Tube Cancer and Epithelial Ovarian Cancer, is actively recruiting participants, sponsored by AbbVie.

RECRUITING
Registry status
Phase 2
Development phase
140 participants
Enrollment target
20
Study locations

Study Summary

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess the safety and efficacy of neoadjuvant carboplatin and mirvetuximab soravtansine in participants with folate receptor alpha (FRα) -expressing advanced-stage serous epithelial ovarian, fallopian tube or primary peritoneal cancer (EOC). Mirvetuximab Soravtansine (MIRV) is an investigational antibody drug conjugate designed to selectively kill cancer cells. The antibody (protein) part of MIRV targets tumors by delivering a cell-killing drug to cancer cells carrying a protein called folate receptor alpha (FRα). This is a single arm study in adult participants with advanced-stage Fédération Internationale de Gynécologie et d'Obstétrique (FIGO) III-IV FRα-expressing serous EOC. Around 140 participants will be enrolled in the study at approximately 80 sites in the United States. Participants will receive intravenous infusion of MIRV in combination with carboplatin on day 1 of each cycle, every 21 days for up to 6 - 9 Cycles. The total study duration will be approximately 3 years . There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.

Conditions Studied

Fallopian Tube Cancer Epithelial Ovarian Cancer Primary Peritoneal Cancer Neoadjuvant

Interventions

  • DRUG Bevacizumab
  • DRUG Carboplatin
  • DRUG Mirvetuximab Soravtansine

Study Locations (20)

California

  • Scripps Mercy Hospital /ID# 276891 - San Diego
  • California Pacific Medical Center /ID# 275329 - San Francisco
  • Ridley Tree Cancer Center /ID# 275219 - Santa Barbara

Louisiana

  • Women'S Cancer Care /ID# 276469 - Covington
  • University Medical Center New Orleans /ID# 274755 - New Orleans
  • Trials 365 /ID# 274310 - Shreveport

Alabama

  • University of Alabama at Birmingham (UAB) Hospital /ID# 274793 - Birmingham
  • Usa Mitchell Cancer Institute /ID# 276022 - Mobile

Connecticut

  • Danbury Hospital, Western Connecticut Health Network /ID# 274783 - Danbury
  • Norwalk Hospital /ID# 274561 - Norwalk

Florida

  • Jupiter Medical Center /ID# 276616 - Jupiter
  • Mount Sinai Medical Center /ID# 274868 - Miami

Illinois

  • Rush Md Anderson Cancer Center /ID# 274926 - Chicago
  • OSF St. Francis Medical Center /ID# 274752 - Peoria

Indiana

  • Parkview Research Center /ID# 274338 - Fort Wayne
  • Indiana University Melvin and Bren Simon Cancer Center /ID# 275492 - Indianapolis

Kentucky

  • Baptist Health Lexington /ID# 275218 - Lexington

Trial Details

FieldValue
Enrollment Target 140 participants
Start Date 2025-11-21
Est. Completion 2030-02
Phase Phase 2

Sponsor

AbbVie

526 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06890338

The ClinicalTrials.gov registry entry for NCT06890338 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 254-participant average among 85 other Fallopian Tube Cancer trials with a reported enrollment target (45% lower). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Fallopian Tube Cancer appearing as the primary indexed condition, and to 3 interventions - of which Bevacizumab is the first listed.

NCT06890338 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Louisiana, Alabama.

Frequently Asked Questions

What is clinical trial NCT06890338 about?

NCT06890338 is a clinical study titled "A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.". Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess the safety and efficacy of neoadjuvant carboplatin and mirvetuximab soravtansine in participants with folate receptor alpha (FRα) -expressing advanced-stage serous e...

What is the current status of trial NCT06890338?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 140 participants. The study started on 2025-11-21. Estimated completion is 2030-02.

What conditions does trial NCT06890338 study?

This clinical trial studies the following conditions: Fallopian Tube Cancer, Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Neoadjuvant.

What interventions are being tested in trial NCT06890338?

The interventions under investigation include: Bevacizumab (DRUG), Carboplatin (DRUG), Mirvetuximab Soravtansine (DRUG).

Who is sponsoring clinical trial NCT06890338?

This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06890338 being conducted?

This trial has 20 study locations across Alabama, California, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Fallopian Tube Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Fallopian Tube Cancer

All registered trials for this condition

Epithelial Ovarian Cancer

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.